The primary objective of this study was to describe neurologists' population of patients treated with pramipexole and suffering from Parkinson's disease (so called 'primary care' population). The secondary objectives were: * Evaluate the mean dose of pramipexole prescribed under actual conditions of use depending on the severity of the disease. * Evaluate the reasons for choosing pramipexole as treatment. * Identify the patient profiles determining the choice of dose of pramipexole prescribed
Study Type
OBSERVATIONAL
Enrollment
497
Assessment of Patient's demographic characteristics
Time frame: 9 months
Assessment of Parkinson's disease characteristics
Time frame: 9 months
Assessment of Severity of the Parkinson Disease (PD)
(levels of severity of the disease were defined with the scientific committee in 5 stages: treatment initiation phase, honeymoon phase, therapeutic insufficiency phase, start of motor complications phase and advanced motor complications phase)
Time frame: 9 months
Assessment of Disease Stage Stage according to Hoehn and Yahr and Unified Parkinson Disease Rating Scale III (UPDRS III) scores
Time frame: 9 months
Description of the actual treatments of PD
Time frame: 9 months
Evaluation for reasons for choosing pramipexole as treatment
Time frame: 9 months
Assessment of Treatment history
3 subgroups: Initiation: no antiparkinson treatment before the implementation of pramipexole Switch: at least one dopamine agonist replaced by pramipexole Add on: pramipexole is implemented in addition to the previous treatment
Time frame: 9 months
Evaluation of the state of health perceived by the patient using the questionnaire EQ-5D
Time frame: 9 months
Number of patients with adverse events
Time frame: 9 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.